Clinical Trial Update: Bexarotene Amyloid Treatment for Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating bexarotene as an amyloid-targeting treatment for Alzheimer's disease has completed, with results posted in 2016. Sponsored by …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Targretin (bexarotene)

Snippet

Sponsor: The Cleveland Clinic | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED | Results posted: 2016-02-12